News

Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence.

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard therapy in patients with early breast cancer.

Stephen M. Ansell, MD, PhD, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology Annual Meeting in the advanced stage Hodgkin lymphoma space.

In a first-in-human trial, AMG 193, a drug targeting a specific mutation in tumors, showed promising results in reducing tumor size and spread in various cancers, with an acceptable safety profile.

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease control.

The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.

Non-operative management showed promising results for patients with mismatch repair proficient locally advanced rectal cancer, preserving organs without compromising survival.

Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress.

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib showed potential as a novel approach for patients with HR+/HER2+ breast cancer.

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.

The RAPSON trial found that receiving radium-223 prior to docetaxel in patients with metastatic castration-resistant prostate cancer improved quality of life and tolerability compared to the reverse sequence, without affecting progression-free survival or overall survival.

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in patients with hepatocellular carcinoma.

Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard chemotherapy in patients with advanced breast cancer.

Following promising preliminary findings from a phase 1 study, the FDA granted P-BCMA-ALLO1 regenerative medicine advanced therapy designation in relapsed/refractory multiple myeloma.

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

Sarah Sammons, MD, provides an overview of the DESTINY-Breast03 trial.

In the NIAGARA trial, significant event-free survival and overall survival gains were observed with neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab in cisplatin-eligible bladder cancer.

Patient-reported outcomes from DESTINY-Breast06 show trastuzumab deruxtecan improved time to deterioration for pain and other subscores, with no decline in overall QOL in either arm in the HER2 low/ultralow breast cancer setting.

Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not statistically significant.

In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.

Long-term findings from KEYNOTE-006, a phase 3 trial, support pembrolizumab as a standard-of-care for patients with advanced melanoma.

TORL-1-23 was well tolerated and showed efficacy in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Nivolumab, alone or with ipilimumab, significantly improved 10-year overall and melanoma-specific survival vs ipilimumab alone in advanced melanoma, according to final phase 3 CheckMate 067 trial data.

Datopotamab deruxtecan elicited encouraging antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

Longer follow-up from the phase 3 AMBASSADOR trial showed adjuvant pembrolizumab to demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.

RP1 with nivolumab treatment for patients with melanoma after progression on anti–PD-1 offers durable responses and a favorable safety profile, as shown in the IGNYTE study.

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free and overall survival rates vs those given olaparib alone.

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer.